Equity Clock

Arithmetic Average Seasonal Chart

Geometric Average Seasonal Chart

IMRN Relative to the S&P 500

IMRN Relative to the Sector

Seasonal Chart Analysis

Analysis of the Immuron Limited (NASD:IMRN) seasonal charts above shows that a Buy Date of December 28 and a Sell Date of March 22 has resulted in a geometric average return of 77.72% above the benchmark rate of the S&P 500 Total Return Index over the past 12 years. This seasonal timeframe has shown positive results compared to the benchmark in 5 of those periods. This is a poor rate of success and the return strongly outperforms the relative buy-and-hold performance of the stock over the past 12 years by an average of 71.09% per year.

The seasonal timeframe correlates Poorly with the period of seasonal strength for the Healthcare sector, which runs from April 25 to December 4. The seasonal chart for the broad sector is available via the following link: Healthcare Sector Seasonal Chart.

Immuron Ltd is a clinical-stage biopharmaceutical company focused on the development and commercialization of a novel class of immunomodulator polyclonal antibodies to treat liver diseases, infectious diseases and other immune-mediated diseases, such as colitis. The company’s product, IMM-124E, is a proprietary immunomodulatory agent targeted at GI immune-mediated diseases including fatty liver diseases. The company functions in two segments namely, Research and Development and Hyperimmune products.

To download IMRN seasonal chart data, please log in or Subscribe.

Stocks mentioned in this post: IMRN